Am I a Candidate for GLP-1 Weight Loss in Las Vegas?
By Charles Kamen, MD, board-certified neurologist
Tirzepatide and semaglutide are both FDA-approved, once-weekly injectable GLP-1 medications for chronic weight management, but they are not the same drug: semaglutide activates a single receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP) and produced greater average weight reduction in the one trial that compared them directly — a study in type 2 diabetes whose main measure was blood sugar, not weight. [3]
The more useful first question, though, is not which drug — it is whether you are even a candidate, and what to ask your physician. This guide is for patients in Las Vegas and Henderson who want to understand how a physician actually makes that decision, rather than ordering medication from a website. For the drug-versus-drug breakdown, see the full side-by-side comparison.
Dr. Charles Kamen, MD, a board-certified neurologist at LiveNow Longevity in Las Vegas, chooses between these medications only after a complete evaluation — never by default or by dose. Individual results vary with any approach.
How are tirzepatide and semaglutide different?
The core difference is how many incretin pathways each drug engages. Semaglutide is a single-receptor GLP-1 agonist; tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors. Engaging two pathways is the proposed reason tirzepatide produced greater average weight reduction than semaglutide in the single trial that compared them head to head. [3]
Both medications are FDA-approved for chronic weight management in adults who meet specific clinical criteria, both are dosed as weekly subcutaneous injections, and both mimic gut hormones that slow gastric emptying and signal fullness to the brain. Each was established in its own large weight-management trial — tirzepatide [1] and semaglutide [2] — and neither is a stand-alone solution: each works best combined with diet, training, sleep, and behavior.
- Semaglutide — single GLP-1 receptor agonist; weekly subcutaneous injection; FDA-approved for chronic weight management.
- Tirzepatide — dual GLP-1 and GIP receptor agonist; weekly subcutaneous injection; FDA-approved for chronic weight management.
- Shared mechanism — both slow gastric emptying, reduce appetite, and improve how the body responds to insulin, which is why they also support blood sugar.
- Shared requirement — both work best with diet, training, and sleep; neither is a stand-alone solution.
Tirzepatide and Semaglutide Side by Side
The table below reports what the current FDA-approved labels say about how each medication is given. It is a summary of published labelling, not a dosing plan — your own prescription and the schedule Dr. Kamen sets with you always govern.
One row deserves particular attention, because it is the detail most often reported incorrectly: the two products do not permit the same injection sites.
| Tirzepatide (Zepbound) | Semaglutide (Wegovy) | |
|---|---|---|
| Receptors activated | Two — GLP-1 and GIP | One — GLP-1 |
| Injection frequency | Once weekly | Once weekly, same day each week |
| Sites you may inject yourself[4][5] | Abdomen or thigh only. The back of the upper arm is for injection by another person | Abdomen, thigh, or upper arm |
| Starting dose | 2.5 mg weekly for 4 weeks — labelled as initiation only, not a maintenance dose | 0.25 mg weekly for weeks 1–4 |
| Escalation pattern | To 5 mg, then in 2.5 mg steps after at least 4 weeks at the current dose | 0.5 mg, then 1 mg, then 1.7 mg, at four-week intervals |
| Labelled maximum | 15 mg once weekly | 7.2 mg once weekly |
| Missed dose window | Within 4 days (96 hours) | Not stated in the same terms |
What the Trials Actually Measured
Published average weight reduction is the number most people arrive looking for, so it is worth setting out precisely — along with which trial produced it and in whom, because those details change the answer substantially.
Read down the columns rather than across them. As the note beneath the table explains, these are not all measuring the same thing.
| Trial | Drug and dose | Population | Duration | Mean weight change | Placebo |
|---|---|---|---|---|---|
| SURMOUNT-1[1] | Tirzepatide 5 mg 10 mg 15 mg | Obesity, without diabetes (n=2,539) | 72 weeks | −15.0% −19.5% −20.9% | −3.1% |
| STEP 1[2] | Semaglutide 2.4 mg | Overweight or obesity, without diabetes (n=1,961) | 68 weeks | −14.9% | −2.4% |
| SURMOUNT-2[6] | Tirzepatide 10 mg 15 mg | Obesity with type 2 diabetes (n=938) | 72 weeks | −12.8% −14.7% | −3.2% |
Who is a candidate for each?
The right choice depends on the patient, not the medication. A physician-led Las Vegas weight management evaluation weighs BMI, prior weight-loss attempts, medical history, current medications, lab work, and personal goals before either drug is considered.
In general terms, the two medications tend to fit different patients:
- Tirzepatide may be considered for patients who have plateaued on semaglutide, those with significant weight to lose, and those who tolerate GLP-1 medications well.
- Semaglutide may be considered for first-line therapy, milder weight-loss goals, and specific comorbidities such as type 2 diabetes.
- Neither is right for everyone — for some patients the appropriate answer is a different approach entirely.
What you actually want to lose: fat, not muscle
The goal of GLP-1 therapy is not a lower number on the scale — it is losing metabolically harmful visceral fat while protecting muscle. Rapid weight loss of any kind can strip lean muscle alongside fat, which is why supervised protocols pair these medications with protein and resistance training.
Visceral fat — the fat packed around your organs — is the fat that most affects long-term metabolic and cardiovascular health, so losing it rather than just losing weight is the real target. Muscle, meanwhile, is what keeps your metabolism high, your blood sugar stable, and your body strong as you age, so preserving it is a core part of the plan, not an afterthought.
How the clinic protects muscle while you lose fat
Dr. Kamen's protocols emphasize adequate protein intake, resistance training, and gradual dose titration so that weight comes off as fat rather than muscle. Lab work and body-composition tracking over time — not the bathroom scale alone — show whether the plan is actually improving your metabolic health.
How a Las Vegas physician chooses between them
At our Las Vegas peptide clinic, the choice between tirzepatide and semaglutide is made after a complete medical evaluation with Dr. Charles Kamen, MD. The $88 evaluation includes a clinical consultation, lab work, and a goal-based discussion — not an automatic prescription.
We do not auto-prescribe the highest-dose version of either medication. We do not promise specific weight-loss results. We design protocols individually, supervise your care over time, and adjust as your body responds. If neither medication is appropriate, you get that answer directly — because the right answer is a medical decision, not a marketing claim or a TikTok video.
A Neurologist's View: Appetite Begins in the Brain
Both drugs work largely in the brain. GLP-1 and GIP receptors sit in the hypothalamus and brainstem — the same appetite-regulating circuits Dr. Kamen works with as a neurologist — which is why these medications reduce hunger and cravings rather than simply shrinking the stomach.
That central mechanism is also why response varies so much between patients: appetite, reward, and satiety are wired differently in every brain. A neurologist's read on how your nervous system governs hunger, energy, and sleep informs which medication and dose are likely to fit, and helps flag side effects like nausea or fatigue early, when they are easiest to manage.
Key Takeaways
- Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist, and tirzepatide produced greater average weight reduction in head-to-head trials.
- Both are FDA-approved, once-weekly subcutaneous injections for chronic weight management, and both require lifestyle support to work.
- The right choice depends on the patient — BMI, history, medications, labs, tolerance, and goals — not on marketing or drug preference.
- Tirzepatide is often considered after a semaglutide plateau or for significant weight to lose; semaglutide is often a first-line choice, including with type 2 diabetes.
- The real target is losing visceral fat while preserving muscle, which is why protocols add protein, resistance training, and monitoring.
- Dr. Kamen, a board-certified neurologist, selects between them only after an $88 medical evaluation with labs — and will tell you if neither fits.
Common Questions
Which is better, tirzepatide or semaglutide?
There is no universal "better" — the right answer depends on your body, your history, your goals, and your response over time. A physician-led evaluation in Las Vegas can help you choose. See our <a href="/peptide-clinic-las-vegas">Las Vegas peptide clinic</a> page to schedule.
How much do tirzepatide and semaglutide cost in Las Vegas?
Protocol costs depend on the medication, dose, and your individualized plan. The initial medical evaluation is $88. See our <a href="/blog/peptide-therapy-cost-las-vegas">peptide therapy cost in Las Vegas guide</a> for the full breakdown.
Do you serve Henderson patients for weight management?
Yes — the majority of our patients come from Henderson, Green Valley, Anthem, and Seven Hills. See our <a href="/peptide-clinic-henderson">Henderson peptide clinic page</a>.
Will I lose muscle on tirzepatide or semaglutide?
Any rapid weight loss can reduce muscle along with fat, so this is a real concern. Supervised protocols counter it with adequate protein, resistance training, and gradual dose increases, and Dr. Kamen tracks body composition over time to confirm you are losing fat while preserving muscle.
Do these medications help blood sugar, not just weight?
Yes. Both mimic gut hormones that improve how your body responds to insulin, which is why GLP-1 medications lower blood sugar and are used in type 2 diabetes. For many patients, better insulin sensitivity and reduced visceral fat matter as much as the weight loss itself.
Can I just buy tirzepatide or semaglutide online?
You can find websites that ship it, but these are prescription medications with real side effects, dosing decisions, and monitoring needs. A local evaluation with lab work protects you from wrong-dose escalation and catches problems early. Ordering blind skips the supervision that makes GLP-1 therapy safe and effective.
The tirzepatide versus semaglutide question is one of the most common weight-management questions in Las Vegas right now, and the right answer is a complete medical evaluation — not a marketing claim or a TikTok video. Schedule your $88 evaluation at our Las Vegas peptide clinic or our Henderson peptide clinic and Dr. Kamen will help you decide.
References
- Jastreboff AM, et al. NEJM. 2022;387(3):205-216. (SURMOUNT-1)
- Wilding JPH, et al. NEJM. 2021;384(11):989-1002. (STEP 1)
- Frías JP, et al. NEJM. 2021;385(6):503-515. (SURPASS-2 — head-to-head in type 2 diabetes; primary endpoint HbA1c, semaglutide comparator dosed at 1 mg).
- Zepbound (tirzepatide) injection — FDA-approved prescribing information, label revised 4/2026. DailyMed, U.S. National Library of Medicine.
- Wegovy (semaglutide) injection — FDA-approved prescribing information, label revised 6/2026. DailyMed, U.S. National Library of Medicine.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.